Literature DB >> 6673977

The hydrolysis of estramustine phosphate; in vitro studies.

O Gunnarsson, S B Andersson, S A Johansson.   

Abstract

The hydrolysis of estramustine phosphate by enzymes of blood, liver, intestines and prostate of man, dog and rat was studied by using specific analytical methods for the parent compound and some of its metabolites. Estramustine phosphate was stable in blood and plasma of different species but rapidly dephosphorylated to estramustine by liver, intestinal and prostatic enzymes. The prostate was the most active tissue. The ester bond by which nornitrogen mustard is linked to estradiol-17-phosphate was slowly cleaved by enzymes from the liver and prostate of the rat, dog and man. The dog tissues were more effective than those of the rat and man. Intestinal enzymes also exhibited the ability to hydrolyze the carbamic ester, but to a greater extent in the rat than in the dog. It is concluded that, with regard to the metabolism of estramustine, the rat is more similar to man than is the dog. Possible clinical implications of the biotransformation of estramustine phosphate are discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6673977     DOI: 10.1007/BF03188772

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  23 in total

1.  On the inhibition of prostatic phosphatase by tartrate.

Authors:  K JACOBSSON
Journal:  Scand J Clin Lab Invest       Date:  1959       Impact factor: 1.713

2.  Estracyt (NSC 89199) as a substrate for phosphatases in human serum.

Authors:  G L Tritsch; S K Shukla; A Mittelman; G P Murphy
Journal:  Invest Urol       Date:  1974-07

3.  Studies on a nitrogen mustard of estradiol in dogs and rats.

Authors:  R Y Kirdani; G P Murphy; A A Sandberg
Journal:  Proc Soc Exp Biol Med       Date:  1977-05

4.  17 alpha and 17 beta-oxidoreductases of adult female hamster liver and kidney.

Authors:  C D Kochakian
Journal:  J Steroid Biochem       Date:  1982-11       Impact factor: 4.292

5.  Gas chromatographic determination of four metabolites of estramustine phosphate in plasma.

Authors:  S B Andersson; R Lundgren; L Svensson
Journal:  Acta Pharm Suec       Date:  1982

6.  Radioimmunoassay of estramustine phosphate in plasma.

Authors:  B Forsgren; P O Gunnarsson; S A Johansson; R Kant
Journal:  Acta Pharm Suec       Date:  1978

7.  Partial characterization and "quantitation" of a human prostatic estramustine-binding protein.

Authors:  P Björk; B Forsgren; J A Gustafsson; A Pousette; B Högberg
Journal:  Cancer Res       Date:  1982-05       Impact factor: 12.701

8.  Growth and cell survival following treatment with estramustine nor-nitrogen mustard, estradiol and testosterone of a human prostatic cancer cell line (DU 145).

Authors:  B Hartley-Asp; P O Gunnarsson
Journal:  J Urol       Date:  1982-04       Impact factor: 7.450

9.  Pharmacokinetics of estramustine phosphate (Estracyt) in prostatic cancer patients.

Authors:  P O Gunnarsson; S B Andersson; S A Johansson; T Nilsson; G Plym-Forshell
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  Treatment of advanced prostatic carcinoma with estramustine phosphate (Estracyt).

Authors:  G Jönsson; B Högberg; T Nilsson
Journal:  Scand J Urol Nephrol       Date:  1977
View more
  3 in total

1.  Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening.

Authors:  Yongmei Pan; Linhao Li; Gregory Kim; Sean Ekins; Hongbing Wang; Peter W Swaan
Journal:  Drug Metab Dispos       Date:  2010-11-10       Impact factor: 3.922

2.  Impairment of estramustine phosphate absorption by concurrent intake of milk and food.

Authors:  P O Gunnarsson; T Davidsson; S B Andersson; C Backman; S A Johansson
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.

Authors:  C M Perry; D McTavish
Journal:  Drugs Aging       Date:  1995-07       Impact factor: 3.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.